Related by context. All words. (Click for frequent words.) 77 RRMS 75 relapsing remitting MS 71 relapsing multiple sclerosis 70 RRMS patients 69 lupus nephritis 69 PEGylated interferon beta 1a 69 leukemia AML 68 relapsing MS 68 Laquinimod 68 relapsing remitting MS RRMS 68 phase IIb clinical 67 teriflunomide 67 recurrent glioblastoma multiforme 67 metastatic renal cell carcinoma 67 chronic lymphocytic leukemia CLL 67 bendamustine 67 interferon beta 1a 67 HuMax CD4 67 interferon beta 1b 67 relapsed multiple myeloma 67 chronic myeloid leukemia CML 67 diabetic neuropathic pain 67 systemic lupus erythematosus SLE 67 investigational oral 67 BAY #-# 67 Amrubicin 66 lymphoma CTCL 66 Alemtuzumab 66 rheumatoid arthritis RA 66 phase IIa clinical 66 cutaneous T cell 66 vandetanib 66 relapsed refractory multiple myeloma 66 sunitinib malate 66 relapsing remitting 66 Natalizumab 66 Phase Ib clinical 66 multiple sclerosis MS 66 forodesine 66 Adalimumab 66 tocilizumab 66 phase IIb trial 66 idiopathic pulmonary fibrosis IPF 65 acute myelogenous leukemia AML 65 recurrent glioblastoma 65 ACTEMRA TM 65 COPAXONE R 65 Phase Ib study 65 pomalidomide 65 diabetic gastroparesis 65 FTY# 65 lumiliximab 65 RoACTEMRA 65 leukemia ALL 65 Phase IIa clinical 65 PD LID 65 systemic lupus erythematosus 65 Plicera 65 evaluating tivozanib 65 leukemia CLL 65 metastatic castration resistant 65 entinostat 65 relapsing forms 64 laquinimod 64 YONDELIS 64 dirucotide 64 biologic therapy 64 relapsed ovarian cancer 64 ponatinib 64 investigational compound 64 ACTEMRA 64 COPAXONE ® 64 Tocilizumab 64 non metastatic osteosarcoma 64 receptor tyrosine kinase inhibitor 64 cilengitide 64 indolent NHL 64 fingolimod 64 SJIA 64 dirucotide MBP# 64 Annamycin 64 subcutaneously administered 64 PREZISTA r 64 cell lymphoma CTCL 64 Herceptin trastuzumab 64 INCB# [001] 64 tafamidis 64 prostate cancer CRPC 64 axitinib 64 docetaxel chemotherapy 64 Mipomersen 64 sorafenib tablets 64 vidofludimus 64 myelofibrosis 64 superficial bladder cancer 64 Safinamide 64 eculizumab 64 nucleoside analog 64 baminercept 64 oral FTY# 64 Vaprisol 64 MabCampath 64 placebo controlled clinical 64 romidepsin 64 overactive bladder OAB 64 alefacept 64 LY# [003] 63 Ophena TM 63 Gleevec imatinib 63 chronic ITP patients 63 Traficet EN 63 schizophrenia CIAS 63 castration resistant prostate cancer 63 adalimumab Humira 63 BRAF inhibitor 63 VAPRISOL 63 Alzhemed TM 63 Arranon 63 BRIM2 63 Tavocept 63 dasatinib Sprycel 63 octreotide LAR 63 Ambrisentan 63 neurogenic orthostatic hypotension 63 Cimzia ® 63 Rebif ® 63 relapsed CLL 63 pan HDAC inhibitor 63 efalizumab 63 IBS C 63 Sapacitabine 63 Crohn disease 63 VELCADE melphalan 63 ocrelizumab 63 canakinumab 63 mTOR inhibitor 63 Ofatumumab 63 fibromyalgia syndrome 63 Acute Myeloid Leukemia AML 63 CYT# potent vascular disrupting 63 Phenoptin 63 prostate cancer HRPC 63 Torisel 63 post herpetic neuralgia PHN 63 rituximab Rituxan 63 phase IIb study 63 eosinophilic asthma 63 angiogenesis inhibitor 63 docetaxel Taxotere R 63 chronic plaque psoriasis 63 mRCC 63 acute ischemic stroke 63 cabazitaxel 63 immunomodulatory therapy 63 Phase 2b clinical 63 post operative ileus 63 metastatic hormone refractory 63 Parkinson disease PD 63 primary hypercholesterolemia 63 HER2 positive metastatic breast 63 Phase 2b trial 63 Betaferon ® 63 Aflibercept 63 autoantibody positive 63 abatacept 63 invasive candidiasis 63 vemurafenib 63 eltrombopag 63 homozygous familial hypercholesterolemia 63 refractory CLL 63 lomitapide 63 AVONEX ® 63 tezampanel 63 FOLOTYN ® 63 post herpetic neuralgia 63 myelodysplastic syndrome MDS 63 relapsed MM 63 mapatumumab 63 cetuximab Erbitux R 63 alvespimycin 63 Myelodysplastic Syndrome MDS 63 AGILECT R 62 gastrointestinal stromal tumors GIST 62 pertuzumab 62 rilonacept 62 refractory gout 62 APTIVUS r 62 mycophenolate mofetil 62 galiximab 62 chlorambucil 62 ankylosing spondylitis AS 62 Tyrima 62 vascular disrupting agent 62 oral ridaforolimus 62 PRTX 62 methylnaltrexone 62 elotuzumab 62 recurrent GBM 62 Phase 1b trial 62 phase IIa 62 icatibant 62 opioid induced bowel dysfunction 62 TYKERB 62 metastatic RCC 62 ofatumumab 62 docetaxel Taxotere ® 62 Zolinza 62 ACZ# 62 cediranib 62 CIPN 62 Phase IIb trial 62 beta 1a 62 Rheumatoid Arthritis RA 62 ospemifene 62 recurrent ovarian cancer 62 gastrointestinal stromal tumor GIST 62 beta interferon 62 ritonavir boosted 62 Omacetaxine 62 Cloretazine 62 clopidogrel Plavix 62 Xanafide 62 castrate resistant prostate cancer 62 heavily pretreated 62 bosentan 62 SCH # 62 ZOLINZA 62 desvenlafaxine succinate 62 tyrosine kinase inhibitor 62 amrubicin 62 visilizumab 62 anti TNF 62 dacarbazine 62 rheumatoid arthritis 62 Tolvaptan 62 Gleevec resistant 62 sorafenib Nexavar 62 Dasatinib 62 orally bioavailable 62 Gleevec imatinib mesylate 62 VA# [002] 62 rufinamide 62 natalizumab 62 Phase 2a clinical 62 idiopathic thrombocytopenic purpura ITP 62 Seliciclib 62 dexanabinol 62 CHOP chemotherapy 62 INCB# [003] 62 hepatocellular carcinoma HCC 62 REMICADE ® 62 nilotinib 62 relapsed leukemia 62 dexpramipexole 62 Romidepsin 62 refractory CTCL 62 NVA# 62 dyskinesia PD LID 62 Revlimid lenalidomide 62 desvenlafaxine 62 refractory multiple myeloma 62 Velcade bortezomib 62 subcutaneous formulation 62 Lu AA# 62 tolvaptan 62 xanthine oxidase inhibitor 62 ZYBRESTAT 62 dose escalation clinical 62 hypoparathyroidism 62 pancreatic neuroendocrine tumors 62 tasocitinib 62 recurrent genital herpes 62 metaglidasen 62 symptomatic BPH 62 metastatic HRPC 62 CDP# 62 postoperative ileus 62 trabectedin 62 oral prodrug 62 Phase III clinical 62 Zenvia ™ 62 cutaneous T 62 Actemra tocilizumab 62 darapladib 62 protease inhibitor PI 62 Ceflatonin 62 TREANDA 62 phase IIb 62 MAGE A3 ASCI 62 disease modifying 62 TBC# 62 decitabine 62 heterozygous FH 62 abiraterone 62 placebo controlled Phase 62 ILUVIEN ® 62 systemic juvenile idiopathic 62 Vidaza azacitidine 62 davunetide 62 sJIA 62 INTEGRILIN R 62 Raptiva ® 62 OHR/AVR# 62 lapatinib Tykerb 62 azacitidine 62 Hodgkin lymphoma HL 62 Nexavar ® 62 interferon beta therapy 62 Vandetanib 62 postherpetic neuralgia 62 pseudobulbar affect PBA 62 Relapsing remitting MS 62 CEQ# 61 relapsed refractory 61 stage IIIB 61 regorafenib 61 Bezielle 61 Golimumab 61 DAPT 61 HeFH 61 noninfectious uveitis 61 active ankylosing spondylitis 61 alemtuzumab 61 Etanercept 61 KRN# 61 TYSABRI 61 etanercept 61 ProSavin 61 Ilaris 61 follicular NHL 61 AA Amyloidosis 61 Phase IIIb clinical 61 hour bronchodilation 61 NOXAFIL 61 glatiramer acetate 61 selective modulator 61 AA amyloidosis 61 Miraxion 61 erlotinib Tarceva ® 61 Jevtana 61 aHUS 61 Avonex interferon beta 1a 61 Ocrelizumab 61 diabetic macular edema DME 61 gout flares 61 secondary hyperparathyroidism 61 BRIM3 61 sunitinib 61 chronic angina 61 gastrointestinal stromal tumors 61 ELND# 61 hormone refractory prostate cancer 61 partial onset seizures 61 HuLuc# 61 carfilzomib 61 posaconazole 61 inhibitor RG# 61 hyperuricemia 61 primary immunodeficiency PI 61 GW# [003] 61 adult chronic ITP 61 terlipressin 61 IFN beta 61 acute myeloid leukemia AML 61 Telintra 61 calcineurin inhibitor 61 cetuximab Erbitux ® 61 CCR5 antagonist 61 humanized monoclonal antibody 61 atypical antipsychotic 61 Diabetic Macular Edema 61 painful diabetic neuropathy 61 carcinoid syndrome 61 ibandronate 61 anterior uveitis 61 lintuzumab SGN 61 PsA 61 Phase 2b study 61 Nexavar sorafenib 61 Tasimelteon 61 Arcalyst 61 esophageal candidiasis 61 DU #b 61 Cimzia 61 diagnosed multiple myeloma 61 Azedra 61 adalimumab 61 anakinra 61 panitumumab Vectibix 61 levodopa therapy 61 Novantrone 61 diarrhea predominant irritable 61 SUTENT 61 alfa 2a 61 TORISEL 61 TACI Ig 61 Teriflunomide 61 IL# PE#QQR 61 temsirolimus 61 Rebif R 61 tanespimycin 61 Campath alemtuzumab 61 HER2 positive breast cancer 61 varespladib 61 Cimzia R 61 antibody MAb 61 AZILECT R 61 JAK inhibitor 61 investigational drug 61 B CLL 61 romiplostim 61 anti leukemic 61 ganetespib 61 cholinesterase inhibitor 61 Pemetrexed 61 acute promyelocytic leukemia APL 61 LAF# 61 Diabetic Macular Edema DME 61 Sprycel dasatinib 61 Vimpat ® 61 Phase III placebo controlled 61 hypercalcemia 61 ancrod 61 Rituxan rituximab 61 fenretinide 61 AEG# 61 ATL/TV# 61 pivotal Phase III 61 PEGylated Fab fragment 61 zanolimumab 61 Mitoxantrone 61 FAMPYRA 61 LY# [002] 61 IMGN# 61 nitazoxanide 61 acute migraine 61 Sym# 61 Aryplase 61 psoriatic arthritis PsA 61 HGS# 61 HuMax EGFr 61 imatinib resistant 61 Azilect ® 61 Catena ® 61 Raptiva R 61 PRT# 61 CIMZIA ™ 61 cannabinor 61 ofatumumab HuMax CD# 61 PXD# 61 Sandostatin LAR 61 obatoclax 61 weekly subcutaneous injections 61 pulmonary arterial hypertension PAH 61 Phase III randomized 61 TMC# C# 61 chronic HCV infection 61 FASLODEX 61 OncoVEX GM CSF 61 idarubicin 61 acting muscarinic antagonist 61 Mylotarg 61 IV NSCLC 61 proteasome inhibitor 61 Hepatocellular Carcinoma HCC 61 riociguat 61 Fibrillex TM 61 Betaferon R 61 VFEND 61 juvenile idiopathic arthritis JIA 61 placebo controlled Phase III 61 PKC# 61 acute coronary syndromes ACS 61 chronic myeloid 60 Doxil ® 60 hyperphenylalaninemia HPA due 60 EOquin TM 60 neovascular diseases 60 Onrigin 60 SNT MC# 60 dasatinib 60 long acting muscarinic 60 OZURDEX ® 60 Myelofibrosis 60 PNP inhibitor 60 Pyridorin 60 dasatinib Sprycel ® 60 opioid induced constipation 60 relapsed SCLC 60 Proxinium TM 60 atherothrombotic events 60 Degarelix 60 antiepileptic drug 60 Ceflatonin R 60 plus gemcitabine 60 AGILECT ® 60 Tamibarotene 60 hepatitis C HCV 60 dose cohorts 60 stable angina 60 Phase IIa trial 60 AZILECT ® 60 oral anticoagulant 60 TELINTRA 60 somatostatin analogue 60 pharmacodynamic profile 60 plaque psoriasis 60 HuMax CD# 60 acute promyelocytic leukemia 60 IAP inhibitor 60 thalidomide Thalomid 60 Cimzia ® certolizumab pegol 60 tenofovir emtricitabine 60 metastatic CRC 60 daclizumab 60 Romiplostim 60 antithrombotic 60 reslizumab 60 active comparator 60 Cinquil 60 Talabostat 60 T#I mutation 60 rosuvastatin #mg 60 remission induction 60 Hodgkin lymphoma NHL 60 systemic ALCL 60 davunetide intranasal AL 60 vinca alkaloid 60 oral vancomycin 60 bevacizumab Avastin 60 BCR ABL inhibitor 60 Cariprazine 60 Bortezomib 60 MabThera rituximab 60 Fludara 60 Amigal 60 Pegasys ® 60 Belimumab 60 IMC A# 60 rotigotine transdermal patch 60 anticancer agent 60 TEMODAL 60 ximelagatran 60 rheumatoid arthritis psoriatic arthritis 60 Fingolimod 60 intermittent dosing 60 bortezomib Velcade 60 VEGF inhibitors 60 Rotigotine 60 rasagiline tablets 60 virus HCV protease inhibitor 60 TMS Therapy 60 polymerase inhibitor 60 familial amyloidotic polyneuropathy FAP 60 aripiprazole Abilify 60 Actemra 60 cardiac toxicity 60 teduglutide 60 glufosfamide 60 mertansine 60 Temsirolimus 60 KRAS mutations occur 60 opioid induced constipation OIC 60 Multaq R 60 LymphoStat B 60 histone deacetylase HDAC inhibitor 60 developing Bicifadine serotonin 60 FTY# fingolimod 60 HCD# [002] 60 RG# [001] 60 generation purine nucleoside 60 Daclizumab 60 Pazopanib 60 MEK inhibitor 60 recurrent NSCLC 60 IMA# 60 placebo controlled randomized 60 anti TNF alpha 60 biliary tract cancer 60 perampanel 60 NUVIGIL 60 alemtuzumab Campath 60 Uricase PEG 60 basiliximab 60 imatinib Gleevec ® 60 myeloproliferative disorders 60 SEROQUEL 60 juvenile idiopathic arthritis 60 monotherapy 60 CR# vcMMAE 60 allopurinol 60 Certolizumab pegol 60 post menopausal osteoporosis 60 YONDELIS R 60 otelixizumab 60 Fx #A 60 mitoxantrone plus 60 neurological manifestations 60 Behcet uveitis 60 hematological malignancy 60 paroxysmal nocturnal hemoglobinuria PNH 60 Protelos 60 BCR ABL inhibitors 60 TELCYTA 60 angiotensin receptor blocker ARB 60 Cladribine Tablets 60 Chronic Lymphocytic Leukemia CLL 60 unstable angina UA 60 refractory myeloma 60 acyclovir Lauriad R 60 pancreatic NET 60 MIRCERA 60 NP2 Enkephalin 60 PROMACTA 60 alvimopan 60 recurrent malignant glioma 60 relapsed Hodgkin lymphoma 60 pralatrexate 60 ULORIC 60 Zavesca ® 60 HGS ETR2 60 blinded randomized placebo controlled 60 rotigotine 60 multiple myeloma MM 60 iniparib 60 administered subcutaneously 60 radiation sensitizer 60 Targretin 60 MBP# dirucotide 60 vinorelbine 60 TNF inhibitor 60 Crizotinib 60 mg administered orally 60 TYZEKA 60 GAMMAGARD 60 Relapsing Remitting Multiple Sclerosis 60 Cytoxan 60 Phase 1b clinical 60 opioid induced 60 Aviptadil 60 PEGINTRON TM 60 Ophena 60 imatinib Gleevec 60 Voreloxin 60 bazedoxifene 60 TNF alpha inhibitor 60 LEXIVA r 60 vorinostat 60 ataluren 60 cetuximab Erbitux 60 PAOD 60 protein kinase inhibitor 60 severe psoriasis 60 pramlintide 60 assessing T DM1 60 clofarabine 60 raloxifene Evista 60 Blinatumomab 60 anti arrhythmic drug 60 ribavirin RBV 60 Tasigna nilotinib 60 Noxafil 60 refractory NSCLC 60 HCV infected 60 BENLYSTA belimumab 60 infliximab Remicade 59 PDE4 inhibitor 59 Primary IGFD 59 Pirfenidone 59 odanacatib 59 metastatic malignant 59 ADAGIO study 59 rasagiline 59 TRIOLEX 59 alemtuzumab treated 59 CBLC# 59 refractory chronic lymphocytic 59 mTOR inhibitors 59 multiple myeloma 59 acute leukemias 59 methotrexate MTX 59 registrational 59 pramipexole 59 oral rivaroxaban 59 anticancer compound 59 tigecycline 59 Dapagliflozin 59 mesalazine 59 Cutaneous T 59 Tarceva TM 59 dexamethasone Decadron 59 VaD 59 Kepivance 59 goserelin 59 fallopian tube carcinoma 59 risperidone Risperdal 59 rFIXFc 59 oral deforolimus 59 nucleoside analogue 59 everolimus tablets 59 double blinded placebo 59 RezularTM 59 somatostatin analog 59 de novo kidney transplant 59 NSCLC 59 atacicept 59 dimebon 59 LHRH antagonists 59 Phase IIb trials 59 DPNP 59 Vidofludimus 59 GRN# 59 Genz # 59 BARACLUDE ® 59 Archexin 59 depsipeptide 59 multi kinase inhibitor 59 selective androgen receptor modulator 59 small molecule Hedgehog 59 fluticasone furoate 59 mitoxantrone 59 crizotinib PF # 59 boosted protease inhibitor 59 Zerenex 59 Corlux 59 ELACYT 59 prostate cancer mCRPC 59 Abilify aripiprazole 59 antiarrhythmic drug 59 LHON 59 Abbott HUMIRA 59 confirmatory Phase III 59 immune thrombocytopenic purpura ITP 59 sorafenib 59 dose escalation Phase 59 cangrelor 59 ISENTRESS 59 cinacalcet 59 basal cell carcinoma BCC 59 mu opioid receptor antagonist 59 receptor inhibitor 59 refractory metastatic colorectal cancer 59 low dose cytarabine 59 rALLy clinical trial 59 Abatacept 59 bevacizumab Avastin ® 59 plus dexamethasone 59 TG# [003] 59 anti EGFR antibody 59 AP# [003] 59 anti muscarinic 59 Genentech Rituxan 59 relapsed AML 59 carboplatin paclitaxel 59 PEG PAL 59 multicenter randomized placebo controlled 59 ruboxistaurin 59 metastatic malignant melanoma 59 XmAb# 59 gefitinib Iressa 59 Femara letrozole 59 velafermin 59 gemcitabine Gemzar 59 oxaliplatin Eloxatin 59 abatacept Orencia 59 TNF Tumor Necrosis Factor 59 Aclasta 59 Pixantrone 59 Epratuzumab 59 6R BH4 59 AGHD 59 lenalidomide Revlimid R 59 pegylated liposomal doxorubicin 59 hypophosphatasia 59 investigational hepatitis C 59 tiotropium 59 virus HCV infection 59 tesetaxel 59 IV metastatic melanoma 59 Hydroxyurea 59 HQK 59 MACUGEN 59 ceftazidime 59 dose escalation trial 59 bapineuzumab 59 chronic eosinophilic leukemia 59 rindopepimut 59 infliximab 59 Elagolix 59 olanzapine Zyprexa 59 pouchitis 59 DMARD 59 oropharyngeal candidiasis 59 ZYBRESTAT fosbretabulin 59 iclaprim 59 IRESSA 59 etanercept Enbrel 59 R#/MEM # 59 Chronic lymphocytic leukemia 59 HCV SPRINT 59 ARIMIDEX 59 RAPTIVA 59 Avastin bevacizumab 59 Increlex ® 59 lacosamide 59 angiotensin II receptor blocker 59 Genasense ® 59 chronic ITP 59 Quinamed 59 cisplatin chemotherapy 59 refractory epilepsy 59 CA4P 59 investigational pan BCR 59 rituximab 59 Restless Legs Syndrome RLS 59 CIMZIA TM 59 Cethrin 59 glioblastoma multiforme GBM 59 Systemic Juvenile Idiopathic 59 Elotuzumab 59 lintuzumab 59 telcagepant 59 Lixivaptan 59 cholinesterase inhibitors 59 PRX # 59 ADHF 59 rhIGF-I/rhIGFBP-3 59 elacytarabine 59 Rasagiline 59 FOLFIRI 59 chronic idiopathic thrombocytopenic purpura 59 Firazyr 59 atypical Hemolytic Uremic Syndrome 59 TRANSFORMS 59 Dacogen injection 59 Apixaban 59 ® natalizumab 59 HoFH 59 investigational therapies 59 omega interferon 59 refractory acute myeloid 59 bardoxolone methyl 59 Treanda 59 steroid refractory ulcerative 59 telaprevir dosed 59 uveitis 59 CIMZIA TM certolizumab pegol 59 Evoltra 59 dopamine agonist 59 cladribine 59 nab paclitaxel 59 bicalutamide 59 Phase Ib II 59 unresectable stage 59 tipranavir 59 telbivudine 59 Neovascular AMD 59 LIALDA 59 FSAD 59 Irinotecan 59 standard chemotherapy regimen 59 nucleotide analog 59 ANG# 59 Xerecept 59 temozolomide 59 EVIZON 59 erlotinib 59 Erbitux cetuximab 59 mg BID 59 Symadex 59 Luteinizing Hormone Releasing Hormone 59 liposomal formulation 59 metastatic renal cell 59 safinamide 59 ISIS # 59 MELAS 59 R roscovitine 59 prucalopride 59 imatinib mesylate 59 dextromethorphan quinidine 59 Vilazodone 59 placebo dexamethasone 59 Eltrombopag 59 metastatic GIST 59 Cannabinor 59 REVLIMID lenalidomide 59 entecavir 59 IAP inhibitors 59 dosing regimens 59 Maraviroc 59 pulmonary arterial hypertension 59 Campath ® 59 ADP receptor antagonist 59 radezolid 59 interferon alfa 2b 59 Microplasmin 59 myelodysplastic syndromes 59 refractory cutaneous T 59 Fampridine SR 59 APTIVUS 59 peginterferon alfa 2a 59 RLAI 59 TTF Therapy 59 Rivaroxaban 59 uric acid lowering 59 sipuleucel T 59 AVASTIN 59 generalized anxiety disorder GAD 59 GSK# [001] 59 AEGR 59 Aplidin 59 anti CD3 antibody 59 EFFEXOR XR 59 duodenal ulcer 59 donepezil 59 Abiraterone acetate 59 candesartan cilexetil 59 EDEMA3 59 huN# DM1 59 retinal vein occlusion 59 Mirapexin 59 tecarfarin 59 phase Ib 59 enzastaurin 59 CorVue ™ 59 bortezomib 59 Leber Hereditary Optic Neuropathy 59 pegylated interferon alfa 2a 59 NATRECOR R 59 Rilonacept 59 myelodysplastic myeloproliferative diseases 59 Chronic Myeloid Leukemia 59 pediatric Crohn disease 59 PLX# 59 Phase IIIb study 59 Omnitarg 59 echinocandin 59 ziconotide 59 entacapone 59 irinotecan chemotherapy 59 Exjade 59 SCCHN 59 PEGylated anti 59 acetylcholinesterase inhibitor 59 Dalbavancin 59 Peginterferon alfa 2b 59 RhuDex ® 59 Telavancin 59 idiopathic Parkinson disease 59 HRPC 59 renal cell carcinoma 59 ambrisentan 59 exemestane Aromasin 59 HGS ETR1 59 Dacogen decitabine 59 atypical antipsychotic medication 59 vicriviroc 59 interferon therapy 59 INSPIRE Trial Phase III 59 betrixaban 59 dosing cohorts 59 pegfilgrastim 59 lixisenatide 58 clazosentan 58 Phase #/#a 58 Asentar 58 Neurodex 58 MBP# [001] 58 Pathway Inhibitor 58 capecitabine Xeloda R 58 proton pump inhibitor 58 VELCADE 58 diabetic macular edema 58 pegylated interferons 58 T2DM 58 severe hypercholesterolemia 58 Alzheimer disease AD 58 sunitinib Sutent ® 58 Clolar 58 CYPHER Stent 58 Cimzia TM 58 refractory AML 58 febuxostat 58 venlafaxine XR 58 diabetic nephropathy 58 peripherally acting 58 Omacetaxine mepesuccinate 58 LUX Lung 58 omacetaxine mepesuccinate 58 Phase 2a trial 58 calcineurin inhibitors 58 lorvotuzumab mertansine 58 randomized multicenter 58 virological failure 58 Desmoteplase 58 Ozarelix 58 Phase 1b 58 INCB# [002] 58 T DM1